Sascha Dietrich

Sascha Dietrich

Josef Schneider Str. 2
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 282 publications

Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.

Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.

Journal: Leukemia & lymphoma
Published: June 10, 2026

Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation.

Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation.

Journal: Frontiers in immunology
Published: May 30, 2026

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.

Journal: Annals of hematology
Published: May 15, 2026

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation
Published: March 08, 2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

Prognostic impact of bone marrow iron and serum ferritin in patients with myelodysplastic syndromes.

Prognostic impact of bone marrow iron and serum ferritin in patients with myelodysplastic syndromes.

Journal: Annals of hematology
Published: February 06, 2026

Impact of early tacrolimus exposure on outcomes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Impact of early tacrolimus exposure on outcomes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Journal: Annals of hematology
Published: January 26, 2026

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

Journal: HemaSphere
Published: January 20, 2026

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Journal: Blood
Published: January 05, 2026

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Journal: Blood
Published: January 05, 2026

Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Journal: JCO clinical cancer informatics
Published: December 23, 2025
Showing 1-12 of 282

Last Updated: 09/26/2026